Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFTAROLINE FOSAMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFTAROLINE FOSAMIL.
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFTAROLINE FOSAMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
600 mg IV every 12 hours infused over 1 hour
None Documented
None Documented
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic